

Supplementary Table of Contents

Supplementary Table 1. Longitudinal Changes in Prescription Patterns of Mineral Bone Disease Medications (N=234)

Supplementary Table 2. Comparison of Serum Phosphorus Levels between Patients in the Study Cohort (N=234) and Patients who Stopped Combination Therapy with SO within 120 Days of SO Initiation (N=222)

Supplementary Table 3. Comparison of Demographic Characteristics between Study Cohort and a Historic Cohort of Hemodialysis Patients Prescribed SO Monotherapy

Supplementary Table 1. Longitudinal Changes in Prescription Patterns of Mineral Bone Disease Medications (N=234)

		Intravenous Vitamin D		Oral Vitamin D		Cinacalcet	
		Use, %	Doxercalciferol dose, µg/week	Use, %	Calcitriol dose, mcg/day	Use, %	Cinacalcet dose, mg/day
Baseline	-Q1 (referent)	50.0	43.3	45.7	2.1	50.0	49.4
Follow-up	Q1	49.6	41.7	52.6 *	1.5	54.7 *	51.3 *
	Q2	49.3	42.0	53.8 *	1.4	53.4 *	51.1 *
	Q3	47.8 *	34.5 †	54.5 †	0.9 *	59.0 *	53.1 †
	Q4	43.7 †	36.6 *	57.5 †	0.7 *	68.0 †	52.4 †
P-Value		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001

Note: Data are presented as least-squared means or %

P-values compare quarterly summary measures with –Q1 as the referent. * $P < 0.05$; † $P < 0.001$

Supplementary Table 2. Comparison of Serum Phosphorus Levels between Patients in the Study Cohort (N=234) and Patients who Stopped Combination Therapy with SO within 120 Days of SO Initiation (N=222)

Groups	n	Baseline mean sP			Follow-up mean sP				P-Value
		Month -3	Month -2	Month -1 (referent)	Month 1	Month 2	Month 3	Month 4	
Study cohort: Patients who completed ≥ 120 days of combination therapy with SO (N=234)									
All patients in the study	234	6.61	6.81	6.79	6.36 †	6.35 †	6.29 †	6.13 †	<0.001
Excluded; patients who completed < 120 days of combination therapy with SO (N=222)									
Patients who were excluded	222	6.50 *	6.66	6.80	6.39 †	6.37 †	6.38 †	6.30 †	<0.001
Discharged from FKC or disenrolled from FreseniusRx ^a	49	6.27 *	6.60	6.50	6.20 *	6.03 *	6.47	6.07 *	0.006
Switched from (SO + non-SO PB) to SO monotherapy	26	6.35	6.44	6.60	6.0	6.64	6.05	6.26	0.14
Switched from (SO + non-SO PB) to non-SO PB monotherapy	95	6.56 *	6.62	6.92	6.56 *	6.56 *	6.47 *	6.46 *	<0.001
Switched from (SO + non-SO PB) to non-SO PB polytherapy	52	6.66	6.90	7.0	6.39 *	6.66	6.48 *	6.61	0.011

Note: Data are presented as least-squared means

P-values compare summary measures with month -1 as the referent. * $P < 0.05$; † $P < 0.001$

^a Some patients were discharged from FKC (transplantation, transfer to non-FKC facilities, withdrawal from dialysis, or death), and did not have follow-up pharmacy or lab records. Results for patients who disenrolled from FreseniusRx, but continued to receive HD care at FKC are presented.

Abbreviations: FKC, Fresenius Kidney Care; FreseniusRx, Fresenius specialty pharmacy; HD, hemodialysis; PB, phosphate binder; ref, reference; sP, serum phosphorus; SO, sucroferic oxyhydroxide

Supplementary Table 3. Comparison of Demographic Characteristics between Study Cohort and a Historic Cohort of Hemodialysis Patients Prescribed SO Monotherapy

Measure	Study Cohort	Comparative Cohort*
Number of patients	234	1029
Age, years	51.8 ± 13.4	52.4 ± 13.0
Dialysis vintage, months	55.0 ± 45.6	53.3 ± 46.7
Female, n (%)	98 (41.9)	474 (46.1)
Body mass index, kg/m ²	33.1 ± 8.9	32.3 ± 8.8
Race/ethnicity, n (%)		
White	123 (52.6)	522 (50.7)
Black	92 (39.3)	452 (43.9)
Other / unknown	19 (8.1)	55 (5.4)
Hispanic/Latino	36 (15.4)	163 (15.8)
Comorbidities, n (%)		
Diabetes mellitus	138 (59.0)	605 (58.8)
Congestive heart failure	69 (29.5)	215 (20.9)
Charlson Co-Morbidity Index	4.7 ± 2.0	3.8 ± 1.6 ^a
Baseline phosphate binder ^b , n (%)		
Sevelamer	96 (41)	629 (61.1)
Calcium acetate	59 (25.2)	242 (23.5)
Lanthanum carbonate	7 (3)	72 (7.0)
PB polytherapy ^c	56 (23.9)	-
No PB recorded	16 (6.8)	-
Recorded switch between PB ^d	-	86 (8.4)
PB pill burden, pills/d	12.3 ± 6.4	9.6 ± 4.3
Clinical lab measures at baseline		
Serum phosphorus, mg/dL	6.70 ± 1.43	6.93 ± 1.39
Serum calcium, mg/dL	9.14 ± 0.63	9.24 ± 0.69
Intact PTH, pg/mL	572 ± 493	578 ± 480
Serum albumin, g/dL	4.0 ± 0.3	4.0 ± 0.3

Note: Data are presented as mean ± standard deviation, or n(%)

* Comparative reference population included a cohort of 1029 HD patients who were prescribed SO monotherapy as part of routine clinical care at FKC clinics and previously published ²⁸

^a Charlson comorbidity index was not included in reference 28

^b Last recorded phosphate binder was presented for the study cohort

^c Baseline phosphate binder polytherapy in the study cohort included CaAc + Sev (17%), CaAc + LC (3%), and Sev + LC (3.9%)

^d Recorded switch between phosphate binder therapies in the comparative cohort included patients who switched between Sev and CaAc (5.7%), CaAc and LC (1%), and Sev and LC (1.7%)

Abbreviations: CaAc, calcium acetate; HD, hemodialysis; LC, lanthanum carbonate; PB, phosphate binder; PTH, intact parathyroid hormone; Sev, sevelamer carbonate